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12 Oral PresentationsAverage infused TNC/kg 107 was 2.9 (1.9–5.8) and 4.7 (0.6–9.1)
for the non-cultured and cultured cells respectively, and infused
CD34 cells/kg (105) was 2.2 (1.1–3.4) and 55 (9.1–136) respec-
tively. No toxicities directly attributable to the cultured product,
including infusional, increased acute GVHD, or graft failure
have been observed. Relatively rapid engraftment was observed
in 7 of 8 patients with a median time to engraftment of 16 days
(7 to 34), as compared to 25 days (16 to 48) in patients (n 5 17)
undergoing an identical transplant regimen here, but with 2 non-
cultured CBU. Relative contribution of the expanded and non-cul-
tured grafts over time was determined by a DNA-based assay on
peripheral blood, beginning day 7 post transplant. Engrafted my-
eloid cells present at day 7 were derived almost entirely from the
expanded unit in 7 patients. In 3 of 7, ANC . 500 was observed
at days 7, 9 and 16 and was mainly derived from the expanded
unit, whereas in the other 4 patients who achieved ANC . 500 at
day 13, 16, 20 and 21, myeloid engraftment at day 14 was derived
from the non-cultured cells. Persistent engraftment from the ex-
panded cells has been noted in 2 patients, one through 280 days
post transplant and one who is currently 125 days post transplant
in whom the expanded cells continue to dominate in CD33,
CD14 and CD56 sorted cell fractions. Average follow-up time is
287 days (range 56–680). One patient died on day 462 from com-
plications of VZV myelitis; all other patients are alive and in remis-
sion. Thus, improvement in early myeloid reconstitution may result
from provision of short term repopulating cells and/or of cells able
to facilitate engraftment of the non-cultured unit. These studies
continue with the goal of achieving consistent, rapid engraftment in
recipients of hematopoietic cell transplants to decrease morbidity
and mortality in the early post-transplant setting.
GVH/GVL
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TARGETED PROTECTION OF THE COLON IN THE ABSENCE OF DONOR
ANTIGEN-PRESENTING CELL -DERIVED INTERLEUKIN 23 ALLOWS FOR
SEPARATION OF GRAFT VERSUS HOST AND GRAFT VERSUS LEUKEMIA
EFFECTS
Das, R., Drobyski, W.R. Medical College of Wisconsin, Milwaukee, WI
Separation of graft versus leukemia (GVL) and graft versus host
(GVH) reactivity has been a longstanding but elusive goal in allo-
geneic bone marrow transplantation (BMT). Recent studies from
our laboratory have shown that donor APC-derived IL-23 secre-
tion has a critical role in mediating pathological damage in the co-
lon during GVHD, but has no protective effect in other GVHD
target organs such as the lung and liver. These results demonstrate
the feasibility of regional GVHD protection and raise the question
as to whether such localized protection might be a strategy to sep-
arate GVH and GVL responses. To directly address this question,
we employed a novel, clinically relevant murine model of chronic
myelogenous leukemia (CML). In this model, FVB animals that
have the bcr/abl oncogene under the control of a tetracycline-in-
ducible repressor are used as donor animals (i.e. CML mice).
Lethally irradiated normal FVB mice were transplanted with
equivalent numbers (107) of T cell depleted BM from B6 and
FVB CML animals. Withdrawal of tetracycline from the drinking
water induces expression of the bcr/abl oncogene and the devel-
opment of granulocytic hyperplasia and splenomegaly in
transplanted mice. Additional cohorts of animals were also trans-
planted with the same BM inoculum plus 3.5  106 T cells from
either wild type or IL-23-/- donors to determine if GVL and
GVH effects could be dissociated. Whereas mice that received ad-
junctive B6 T cells succumbed from fatal GVHD, animals trans-
planted with T cells from IL-23-/- mice had significantly
prolonged survival and no evidence of leukemia by blood counts
or pathological examination. In order to address the role of
IL-23 in the GVL response directed against leukemia with more
aggressive kinetics, similar studies were performed using a Balb-
derived A20 leukemia cell line. Transplantation with BM and
spleen cells from IL-23-/- donor mice resulted in significantly pro-
longed survival when compared to mice reconstituted with simi-
larly composed marrow grafts from wild type B6 animals. A
five–fold escalation of the A20 cell dose produced similar protec-
tive results in recipients of IL-23-/- marrow grafts. In conclusion,
these studies show that in the absence of donor APC-derived IL-23, GVHD can be significantly reduced without loss of the GVL
effect. Moreover, our results suggest that targeting of IL-23 may
be a viable clinical strategy to ameliorate that severity of GVHD
without abrogating a GVL response.26
FLAGELLIN, A TLR5 AGONIST, FACILITATES PRODUCTION OF
FOXP31CD41CD251 REGULATORY T CELLS TO MAINTAIN BALANCED
IMMUNE RECONSTITUTION IN ALLOGENEIC BMT WITHOUT GVHD
Hossain, M.S.1, Roback, J.D.2, Gewirtz, A.T.2, Waller, E.K.1 1 Emory
University, Atlanta, GA; 2 Emory University, Atlanta, GA
Background: Graft-vs-host disease (GvHD) and lyphopenia are
the major clinical problems in allogeneic bone marrow transplanta-
tion (BMT). Immunosuppressive drugs are used to control GvHD,
but immunosuppression is often incomplete and patients experience
drug-related toxicities. Donor foxp31CD251CD41 regulatory T
cells are also effective at controlling GvHD, but are expensive and
time consuming to produce. Flagellin, a bacterial protein and
a TLR5 agonist, can culminate production of proinflammatory cyto-
kines and chemokines. In this study we investigated whether flagellin
could facilitate thymic production of donor BM-derived
foxp31CD251CD41 regulatory T cells to control GvHD and reg-
ulate post BMT immune reconstitution.
Methods: Irradiated (11Gy) CB6F1 recipient received 5  106
T cell depleted BM and 5  106 splenocytes from naive C57BL/6
congenic donors. 50 micro gm flagellin/mouse was administered
i.p. 3 hours before irradiation and 24 hours after BMT. Recipients
that received no flagellin were used as control. After 701 days
post transplant recipients were infected with 5  103 pfu
MCMV i.p., sacrificed at different time points and lymphocytes
were harvested from spleen and thymus for analysis. Flow cytom-
etry was used to determine immune reconstitution, normal and
regulatory T cells.
Results: All flagellin-treated recipients survived without GvHD
for 66 days post transplant, while only 65% of the control mice sur-
vived and had chronic GvHD. The number of splenocytes was sig-
nificantly increased in flagellin-treated recipients compared to
control recipients (p 5 0.0006) on day 66-post transplant. Donor
spleen- and BM-derived CD41 and CD81T cells were significantly
higher in the spleen of flagellin-treated recipients compared to con-
trol mice. Flagellin-treated recipients had higher levels of both do-
nor spleen- and BM-derived anti-viral CD81 T cells in the spleen
compared to control recipients. The thymus of flagellin-treated
recipients produced donor spleen- and BM-derived T cells and
foxp31CD251CD41 regulatory T cells, while thymic functions
were severely reduced in control recipients.
Conclusion: Flagellin treatment successfully reduced GvHD, im-
proved survival, enhanced donor T-cell engraftment and produced
regulatory T cells in allo-BMT. Treated recipients had brisk and
persistent cellular immune responses against MCMV infection.
Hence, prophylactic use of flagellin is a novel therapeutic approach
to treat blood cancer patients with allogeneic BMT.27
LYMPHOCYTE RECOVERY IS A MAJOR DETERMINANT OF TRANSPLANT
OUTCOME AFTER MYELOABLATIVE TRANSPLANTATION IN PATIENTS
WITH MYELOID MALIGNANCIES RECEIVING MATCHED UNRELATED
STEM CELL ALLOGRAFTS
Le Blanc, K.1, Remberger, M.2, Barrett, J.3 1 Karolinska Institutet and
Karolinska University Hospital Huddinge, Stockholm, Sweden; 2 Karolin-
ska Institutet, Stockholm, Sweden; 3 National Institute of Health, Bethesda,
MD
A higher lymphocyte count one month after allogeneic stem cell
transplantation (SCT) is associated with better outcome in patients
transplanted from an HLA-identical sibling. However, a predictive
role of the day 30 post-transplant absolute lymphocyte count
(LC30) in unrelated transplants is not defined. We studied the rela-
tionship between LC30 and outcome in 102 patients with myeloid
leukemia receiving myeloablative SCT from matched unrelated do-
nors. Conditioning consisted of cyclophosphamide with Busulphan
(n 5 61) or total body irradiation (n 5 41). Immunosuppression
Oral Presentations 13was cyclosporine with four doses of methotrexate in 97 patients and
other treatments in 5. Overall survival at 5 years was 61% and re-
lapse-free survival was 56%. The incidence of acute GvHD grades
II-IV was 62% in patients with an LC30 of\0.2  109/L, 33% if
the LC30 was 0.2–1.0  109/L and 25% in patients with an LC30
.1.0  109/L (p 5 0.008). Transplant related mortality (TRM)
was 34% in patients with an LC30\0.2  109 versus 19% (LC30
of 0.2–1.0  109) and 0% (LC30 .1.0  109) (p\0.001). Survival
was significantly higher in 17 patients with an LC30 .1.0  109/L,
compared to 67 patients with an LC30 0.2–1.0  109/L, and 18 pa-
tients with \0.2  109/L (91% vs. 60%, vs. 36% p 5 0.02 and
0.001 respectively). When analyzed as a continuous variable in mul-
tivariate analysis, a higher LC30 was associated with a lower inci-
dence of acute GvHD grades II-IV, improved survival, less relapse
and higher relapse-free survival. Plasma levels of cytokines were mea-
sured in 15 subjects between day 12–32 post-transplant (total 21 sam-
ples). Six patients had a low (\0.2109/L) and 9 patients a high (.1.0
 109/L) LC30. Plasma IL-15 was lower in patients with high LC30
(median 32 pg/ml vs. 56.5 pg/ml, p\0.05 log rank sum). These re-
sults indicate that the LC30 is a robust prognostic factor for trans-
plant outcome in matched unrelated as well as matched related
SCT for myeloid malignancies receiving either BM or PBSC with
or without irradiation conditioning. Further research to identify
the transplant conditions leading to prompt lymphocyte recovery
might lead to global improvements in SCT outcome in unrelated
SCT.28
ADOPTIVE TRANSFER OF NKT CELLS REDUCES GVHD SEVERITY VIA AN
IFN-G AND IL-4 DEPENDENT MECHANISM
Leveson-Gower, D.B.1, Olson, J.A.1, Sega, E.I.1, Baker, J.1, Zeiser, R.2,
Negrin, R.S.1 1 Stanford University, Stanford, CA; 2 Albert Ludwig
University Freiburg, Freiburg, Germany
NKT cells, which are CD1d reactive, are thought to play an im-
munoregulatory role in suppressing dysfunctional immune reac-
tions, including graft-versus-host disease (GVHD). However, we
do not know if non-manipulated donor-type NKT can suppress
GVHD or how NKT proliferate and migrate following hemato-
poetic cell transplantation (HCT). We transferred 5.5  105 highly
purified (.95%) NKT (DX51TCR1CD41) from luciferase posi-
tive (luc1) C57BL/6 (H-2b) mice into lethally irradiated Balb/c (H-
2d) recipients with 5 106 T-cell depleted bone marrow (TCD-BM)
from wild-type (WT) C57BL/6 mice, and monitored them by biolu-
minescence imaging (BLI). By day 4 after transfer, a signal was ob-
served in spleen and lymph node (LN) sites, and between days 7
and 10, NKT had also migrated to skin. Total photons emitted
peaked around day 25 after transplantation, followed by a steady de-
cline. To assess the impact of donor-type NKT on GVHD induction
by Tcon, we co-transferred various doses of highly pure WT NKT
at day 0 with 5  106 TCD-BM, followed by 5  105 luc1Tcon at
day 2. We have found that adoptive transfer of as few as 2.5  10 4
NKT can significantly improve survival of mice receiving 5  105
Tcon. Survival with Tcon only was 20% and for Tcon with NKT
was 74%; p 5 0.0023. To determine how NKT reduce GVHD,
we examined intracellular levels of various cytokines in Tcon with
or without 2.5  104 NKT, following HCT. At 8 days after HCT,
mice receiving NKT had fewer TNFa-positive cells from LNs
(CD4: 45% to 27%; CD8 36% to 24%); by day 11, however,
TNFa levels between groups were equivalent. IFN-g levels, which
were high in both NKT treated and untreated groups at day 8
(85%-95%), decreased significantly in NKT treated mice by day
11 (CD4: 40%; CD8: 43%), but were abundant in Tcon only mice
(CD4: 78%; CD8: 80%) (p 5 .0001). NKT from both IL-4 -/-
and IFN-g -/- mice were less effective at suppressing GVHD than
WT NKT, implicating these cytokines in the suppressive mecha-
nism. Finally, we found that NKT do not have a major impact on
the graft-versus-tumor effect of Tcon against a luc1BCL-1 tumor.
These studies indicate that NKT persist in vivo upon adoptive trans-
fer and suppress GVHD, even at extremely low cell numbers, which
is important given the relative paucity of this cell population. The
mechanisms of GVHD suppression appear to be distinct to those
of CD41CD251FoxP31 Treg and involve the production of
IL-4 and IFN-g by NKT and a decrease in Tcon which produce
pro-inflamatory cytokines.29
CEACAM1 REGULATES EXPERIMENTAL GRAFT-VERSUS-HOST-DISEASE
Lu, S.X.1, Willis, L.1, Charbonneau-Allard, A.-M.2, Atallah, R.2,
Holland, A.M.1, Turbide, C.2, Hubbard, V.M.3, Rotolo, J.A.4,
Smith, O.M.1, Suh, D.1, King, C.1, Rao, U.K.1, Yim, N.1,
Kochman, A.1, Bautista, J.L.1, Jenq, R.R.1, Zakrzewski, J.L.1,
Tran, H.1, Penack, O.1, Na, I.-K.1, Chow, M.1, Lin, J.1,
Cabrera-Perez, J.1, Liu, C.5, Murphy, G.6, Alpdogan, O.1,
Blumberg, R.S.7, Macian, F.3, Holmes, K.V.8, Beauchemin, N.2, van
den Brink, M.R.M.1 1 Memorial Sloan-Kettering Cancer Center, New
York, NY; 2 McGill Cancer Center, Montreal, QC, Canada; 3 Albert Ein-
stein College of Medicine, Bronx, NY; 4 Memorial Sloan-Kettering Cancer
Center, New York, NY; 5 University of Florida College of Medicine, Gain-
esville, FL; 6 Brigham and Women’s Hospital, Boston, MA; 7 Brigham and
Women’s Hospital, Boston, MA; 8 University of Colorado Health Sciences
Center, Aurora, CO
Carcinoembryonic antigen associated cell adhesion molecule 1
(Ceacam1) is a type I transmembrane glycoprotein that regulates
numerous processes including bacterial colonization of the gastro-
intestinal lumen and leukocyte function. Ceacam1 is expressed on
gut epithelium and activated T cells, particularly in the intestines.
We found that T cells from Ceacam1-/- mice had elevated phos-
phorylation of STAT3. Upon stimulation with anti-CD31CD28,
IL-2, IL-4, IL-6, or IL-12 in vitro, Ceacam1-/- T cells showed hy-
perphosphorylation of corresponding canonical STAT proteins,
indicating that Ceacam1 can regulate the sensitivity of T cells to cy-
tokines and TCR stimulation. Ceacam1-/- T cells also had defec-
tive anergy induction as measured by IL-2 secretion. This was
associated with decreased cleaved caspase 3 (but not decreased ap-
optosis) and hypophosphorylation of STAT1 upon IFNg treat-
ment. We assessed Ceacam1 regulation of T cells in vivo during
GVHD. Ceacam1-/- T cells caused increased mortality and large
intestinal GVHD, had more profound activation (CD25,
CD62L) and expression of integrin a4b7 and demonstrated selec-
tive infiltration of the intestines. By contrast, Ceacam1-overex-
pressing T cells caused significantly less GVHD mortality and
damage to all target organs, which correlated with decreased prolif-
eration and organ infiltration. We also studied Ceacam1 in recipi-
ents of allogeneic bone marrow transplantation (allo-BMT), and
found that compared to wildtype (WT) recipients, Ceacam1-/- re-
cipients with GVHD showed accelerated mortality and increased
damage to the large intestines and thymus. Donor alloactivated
CD4 T cells in Ceacam1-/- allo-BMT recipients had increased ac-
tivation (CD25), and trafficked preferentially to the mesenteric
lymph nodes, small and large bowel, but had decreased accumula-
tion in the liver and peripheral lymph nodes (PLN). Finally, Cea-
cam1-/- mice were more sensitive to radiation injury as
demonstrated by accelerated kinetics of mortality and decreased
numbers of surviving or regenerating small intestinal crypts. We
conclude that Ceacam1 is an important regulator of alloreactivity
during GVHD through its effects on T cell (allo)activation, prolif-
eration, trafficking, cytokine sensitivity, and anergy. Moreover,
Ceacam1 expression on gut epithelium regulates sensitivity to
radiation injury, T cell alloreactivity, and intestinal GVHD.30
ELAFIN IS A BIOMARKER OF GRAFT VERSUS HOST DISEASE OF THE SKIN
Paczesny, S.1,2, Levine, J.E.1, Hogan, J.2, Crawford, J.1, Braun, T.M.1,
Wang, H.2, Faca, V.2, Zhang, Q.2, Pitteri, S.2, Chin, A.2, Choi, S.W.1,
Kitko, C.L.1, Krijanovski, O.I.1, Reddy, P.1, Mineishi, S.1, Whitfield, J.1,
Jones, D.1, Hanash, S.M.2, Ferrara, J.L.M.1 1 University of Michigan,
Ann Arbor, MI; 2 Fred Hutchinson Cancer Research Center, Seattle, WA
There are no plasma biomarkers specific to any of the three target
organs of acute graft versus host disease (GVHD): skin, GI tract
and liver. We sought to identify a biomarker for skin GVHD in
an initial discovery step using an intact proteomic analysis system.
We compared plasma pooled from ten patients with skin GVHD
only (sGVHD) to ten patients without GVHD (–GVHD) to ten pa-
tients with GI tract GVHD only (giGVHD). Of four candidate
proteins that were both significantly elevated only in the plasma
of sGVHD and that could be measured by ELISA, we selected ela-
fin, an epidermal proteinase inhibitor that is induced by TNF-a and
found in inflamed epidermis. We measured levels of elafin
